NCT03065374终止1 期
A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Immuron Ltd.
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Adverse events incidence
研究概览
简要总结
This study will evaluate the safety and tolerability of IMM-529 together with standard of care (SOC) in patients with Clostridium-difficile Infection.
详细描述
Subjects who provide voluntary written informed consent will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate.
Eligible subjects will be randomized up to 3 weeks post diagnosis of Clostridium-difficile Infection given SOC initiated already.
Each subject will return to the study clinic for assessment and required study procedures on Day 7, Day 14, Week 4, Week 8 and Week 12 post randomization. Treatment duration will be 28 days and follow up will last up to 12 weeks post randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Unformed stools (≥3 loose stools in 24 hours at diagnosis)
- •Positive stool testing for C. difficile: PCR and Toxin B positive; or PCR and GDH positive.
- •Up to 3 weeks of diagnosis with at least 20 subjects within 72 hours of diagnosis
- •Patient or legal representative must have read, understood, and provided written informed consent after the nature of the study has been fully explained.
排除标准
- •History of chronic diarrheal illness such as ulcerative colitis or Crohn's disease
- •Known concurrent severe organ insufficiency:
- •Liver: Decompensated cirrhosis (Any complication of cirrhosis or Child Score ≥7).
- •Cardiovascular: New York Heart Association (NYHA) class IV heart failure, or Ejection fraction <30%.
- •Respiratory: Severe exercise restriction (ie, unable to climb stairs or perform household duties); chronic hypoxia, hypercapnia, severe pulmonary hypertension (>40 mmHg); or respirator dependency Renal: Receiving chronic dialysis or GFR < 15 mL/min/1.73m2
- •Other etiology of diarrhea.
- •Fulminant CDI, as defined by any of the following attributable to CDI:
- •Hypotension (Mean arterial pressure < 65mmHg)
- •Ileus or significant abdominal distention
- •Toxic megacolon
- •End organ damage/failure:
- •Respiratory - Need for mechanical ventilation. Cardiac - Pulmonary edema. Renal - Serum creatinine increase >3x Baseline, GFR decrease >50%, urinary output <0.5mL/kg/hr > 12hrs. Hepatic - Liver failure (INR>1.5, Hepatic encephalopathy), decompensation of cirrhosis, bilirubin > 2.5mg/dL.
- •Severe Clostridium difficile colitis with imminent surgery planned in less than 24 hours.
- •Immunocompromise due to: immunosuppressants, chemotherapy, radiation in the last 3 months, long-term steroids (>10mg >3 months) or high-dose steroids (>40mg > 3 weeks), leukemia or lymphoma in the last 5 years, or HIV.
- •Any active malignancy within the last 5 years apart from localized skin cancer (squamous cell carcinoma or basal cell carcinoma) that was fully excised.
- •Positive pregnancy test within 24 hours of study infusion or an unwillingness to undergo pregnancy testing in females of child-bearing potential. Females capable of child-bearing must agree not to become pregnant from the time of study enrollment until at least 28 days after completion of study treatment period. If a woman is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use 2 acceptable contraceptives (see section 7.4.1.) while participating in the study and for 28 days following the last dose of study drug.
- •Breastfeeding
- •Receipt of other investigational study agent within previous 30 days.
- •Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to study products
- •Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the patient participating in the study or make it unlikely the patient could complete the study.
结局指标
主要结局
Adverse events incidence
时间窗: 12 weeks
Number of adverse events
Adverse events severity
时间窗: 12 weeks
Severity of adverse events
次要结局
- Mortality rate(0, 7, 14 days and 4, 8, 12 weeks)
- Disease symptoms incidence(0, 7, 14 days and 4, 8, 12 weeks)
- Disease symptoms severity(0, 7, 14 days and 4, 8, 12 weeks)
- Recurrence rate(12 weeks)
- Recovery rate(4, 12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult ParticipantsHealthy VolunteersNCT05099822Celgene84
已完成
2 期
Phase IIb Study of Evobrutinib in Subjects With Rheumatoid ArthritisRheumatoid ArthritisNCT03233230EMD Serono Research & Development Institute, Inc.390
已完成
2 期
MP1032 Treatment in Patients With Moderate to Severe COVID-19COVID-19NCT04932941MetrioPharm AG132
终止
2 期
A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple SclerosisRelapsing-remitting Multiple SclerosisNCT02975349EMD Serono Research & Development Institute, Inc.267
已完成
1 期
A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy VolunteersHealthyNCT01080820Chimerix36